Inovio Pharmaceuticals, Inc. (NASDAQ:INO) traded at $27.83 at last check on Tuesday, Jun 30, making a downturn move of -12.2% on its previous day’s price.
Looking at the stock we see that its previous close was $31.69 and the beta (5Y monthly) reads 1.39 with the day’s price range being $26.05 – 30.00. In terms of its 52-week price range, INO has a high of $33.79 and a low of $1.92. The company’s stock has gained about 114.85% over that past 30 days.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $2.61 Million, with a low of $300Million and a high of $5.3 Million. The median projection represents growth adding up to 1819.1% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $24.69 Million, or +500.4% up from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the INO stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 8 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Inovio Pharmaceuticals, Inc. (INO) stock as a Hold, while 3 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the INO stock currently stands at 0, and the current price level is 64.6% off its SMA20 and 92.83% from its 50-day simple moving average. The RSI (14) is pointing at 71.15 while the volatility over the past week is 29.38% and drops to 13.26% over the past one month. The beta value is 1.44, while the average true range (ATR) is currently pointing at 2.96. The average price target for the stock over the next 12 months is $21.88, with the estimates having a low of $8 and a high of $45. These price ends are -71.25% and +61.7% off the current price level respectively, although investors could be excited at the prospect of a -26.34% if the INO share price touches on the median price of $20.5.
Let’s briefly compare Inovio (INO) stock to its peers. We find that today’s price change of -12.2% and +977.89% over the past 12 months for INO competes that of Amgen Inc (AMGN), which has seen its stock price rise 0.62% in the latest trading session and is +25.66% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 2.09% today, and is +10.36% up over the past year, while Vertex Pharmaceutic (VRTX) is also down -12.2% yet its price remains in the green at 977.89% over the same period. Amgen has a P/E ratio of 18.14 compared to Inovio’s 0 and Gilead’s 19.17. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.
Coming back to Inovio Pharmaceuticals, Inc. (NASDAQ:INO), we note that the average 3-month trading volume was 37.37 Million, while that of the preceding 10-day period stands at 110Million. Current shares outstanding are 158.1 Million.
According to data from Thomson Reuters, insiders hold 2.69% of the company’s shares while institutions hold 29.41%. The data shows that short shares as of June 14, 2020, stood at 25.78 Million at a short ratio of 1.06. This represents a 16.3% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 22.92 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +860.3% up in year-to-date price movement.